AR127629A1 - Moléculas de anticuerpo y conjugados - Google Patents

Moléculas de anticuerpo y conjugados

Info

Publication number
AR127629A1
AR127629A1 ARP220103086A ARP220103086A AR127629A1 AR 127629 A1 AR127629 A1 AR 127629A1 AR P220103086 A ARP220103086 A AR P220103086A AR P220103086 A ARP220103086 A AR P220103086A AR 127629 A1 AR127629 A1 AR 127629A1
Authority
AR
Argentina
Prior art keywords
antibody
nucleic acid
nucleic acids
antibody molecule
antibody molecules
Prior art date
Application number
ARP220103086A
Other languages
English (en)
Inventor
Frank Irvine Comer
Yariv Mazor
Srinath Kasturirangan
Qun Du
Chunning Yang
Andrew Grier Buchanan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR127629A1 publication Critical patent/AR127629A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente divulgación se refiere a moléculas de anticuerpo que se unen al receptor del factor de crecimiento epidérmico (EGFR) y/o a c-Met y a conjugados que contienen estas moléculas de anticuerpos. Las moléculas de anticuerpo y los conjugados encuentran aplicación, por ejemplo, en el tratamiento del cáncer. Reivindicación 35: Una composición farmacéutica que comprende una molécula de anticuerpo según una cualquiera de las reivindicaciones 1 a 25, o un conjugado según una cualquiera de las reivindicaciones 26 a 34, y un vehículo farmacéuticamente aceptable. Reivindicación 42: Un ácido nucleico, o una pluralidad de ácidos nucleicos, opcionalmente aislados, que codifican una molécula de anticuerpo según una cualquiera de las reivindicaciones 1 a 25. Reivindicación 43: Un vector de expresión, o una pluralidad de vectores de expresión, que comprende un ácido nucleico o una pluralidad de ácidos nucleicos según la reivindicación 42. Reivindicación 44: Una célula hospedadora recombinante que comprende el ácido nucleico o la pluralidad de ácidos nucleicos según la reivindicación 42, o el vector de expresión o la pluralidad de vectores de expresión de la reivindicación 43. Reivindicación 46: Un método según la reivindicación 45, que comprende además aislar y/o purificar la molécula de anticuerpo.
ARP220103086A 2021-11-10 2022-11-10 Moléculas de anticuerpo y conjugados AR127629A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163263835P 2021-11-10 2021-11-10

Publications (1)

Publication Number Publication Date
AR127629A1 true AR127629A1 (es) 2024-02-14

Family

ID=84387847

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103086A AR127629A1 (es) 2021-11-10 2022-11-10 Moléculas de anticuerpo y conjugados

Country Status (6)

Country Link
US (1) US20230183358A1 (es)
AR (1) AR127629A1 (es)
AU (1) AU2022384597A1 (es)
CA (1) CA3237211A1 (es)
TW (1) TW202336037A (es)
WO (1) WO2023083846A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024002938A1 (en) * 2022-06-27 2024-01-04 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN117659203A (zh) * 2023-12-06 2024-03-08 科弈(浙江)药业科技有限公司 一种抗met/egfr双特异性抗体及其药物偶联物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU2003253048A1 (en) 2002-07-09 2004-01-23 Morphochem Aktiengellschaft Fur Kombinatorische Chemie Tubulysin conjugates
CA2580141C (en) 2004-09-23 2013-12-10 Genentech, Inc. Cysteine engineered antibodies and conjugates
AU2008251608B2 (en) 2007-05-08 2014-03-27 Genentech, Inc. Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
NZ584514A (en) 2007-10-19 2012-07-27 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
CN103140227B (zh) 2010-08-06 2016-01-20 恩多塞特公司 制备微管蛋白细胞溶素的方法
EP2794905B1 (en) 2011-12-20 2020-04-01 MedImmune, LLC Modified polypeptides for bispecific antibody scaffolds
KR102089591B1 (ko) * 2013-07-29 2020-03-18 삼성전자주식회사 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
MX2016013373A (es) 2014-04-11 2017-05-02 Medimmune Llc Derivados de tubulisina.
AU2016349152A1 (en) * 2015-11-03 2018-06-14 Merck Patent Gmbh Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
KR102078292B1 (ko) * 2017-05-30 2020-02-19 주식회사 종근당 신규한 항 c-Met 항체 및 이의 용도

Also Published As

Publication number Publication date
US20230183358A1 (en) 2023-06-15
AU2022384597A1 (en) 2024-06-13
CA3237211A1 (en) 2023-05-19
WO2023083846A1 (en) 2023-05-19
TW202336037A (zh) 2023-09-16

Similar Documents

Publication Publication Date Title
AR127629A1 (es) Moléculas de anticuerpo y conjugados
AR110101A1 (es) Miembros de unión (2)
CY1118467T1 (el) Σκευασματα αντισωματων και πρωτεϊνων υψηλης συγκεντρωσης
BR112022014667A2 (pt) Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos
AR126987A2 (es) Inmunoconjugados
BR112012024964A2 (pt) anticorpo de cadeia única bioespecífico psmaxcd3 de espécies cruzadas específicas, seu processso de preparação, seu uso, vetor, composição farmacêutica e kit
CY1118949T1 (el) Ανθρωπινα αντισωματα που προσδενουν cxcr4 και χρησεις αυτων
AR038568A1 (es) Anticuerpos anti-a beta y su uso
AR094141A1 (es) Composiciones y metodos para proteinas de accion prolongada
BR112012026471A2 (pt) conjugado, processo para a síntese do mesmo, método para imagem de uma célula que expressa um transportador de neurotransmissor que compreende o contato da referida célula com o conjugado, processo para preparar um comporto de fórmula (ii) e (xiv) e composto
BR112019005316A2 (pt) anticorpos monoclonais para morte programada 1 (pd-1)
AR045056A1 (es) Anticuerpos anti-ngf humanos neutralizantes como inhibidores selectivos de la via de ngf
AR087567A1 (es) Anticuerpos anti-tie2 y usos de los mismos
CL2019003407A1 (es) Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407)
AR123537A1 (es) Anticuerpo contra hla-dq2.5 y su uso para el tratamiento de la enfermedad celíaca
BR112021026408A2 (pt) Receptores de célula t que reconhecem a mutação r175h ou y220c em p53
AR115721A1 (es) Anticuerpos que comprenden un polipéptido insertado en la región marco 3
RU2005118752A (ru) Позиционные изомеры пэгилированного интерферона l-2а (конъюгата пэг-ifn-l-2а)
CL2021000549A1 (es) Péptido asociado a tumor (tumap); ácido nucleico; vector de expresión; célula hospedadora recombinante que comprende el péptido; método para producir el péptido; composición farmaceutica; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico (divisional de la solicitud no. 201900460)
BRPI0410562B8 (pt) proteína de veículo e seu método de produção em uma planta, ácido nucleico isolado, vetor de expressão e célula hospedeira
AR095499A1 (es) ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b
BR112023022367A2 (pt) Anticorpos anti-tigit e métodos de uso dos mesmos
BR112023025331A2 (pt) Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
AR124599A1 (es) Constructos de expresión y usos de estos
BR112012014345A2 (pt) peptídeos tmem22 e vacinas incluindo os mesmos